Abstract

Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives

Retrieved on: 
Tuesday, April 2, 2024
Moses Austin, Ohio State University, Edwards Lifesciences, Education, Patient, Global strategy, SVP, Coronary thrombosis, Business development, Radiology, University, Doctors Hospital, Faculty, Senior, Abstract, MD Anderson Cancer Center, Hospital, MitraClip, Baptist Hospital, Interventional radiology, Health, Global marketing

IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.

Key Points: 
  • IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.
  • Dr. Niekamp will be instrumental in advancing Inari’s mission to improve patient care through physician education and new device development.
  • Mr. Benner joins Inari with more than 16 years of senior leadership experience with high-growth and transformational medical technology companies.
  • We are honored to add his talents to our Medical Affairs team,” said Dr. Thomas Tu, Chief Medical Officer of Inari.

Abivax reports 2023 financial results and operational update

Retrieved on: 
Tuesday, April 2, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Research, Herbal cigarette, Exercise, Webcast, Risk, International, Nicotine, NDA, Society, Abstract, Smoking, Safety, FDA, Food, Pharmaceutical industry

Results presented from the Phase 3 participant surveys, showed that 69% of survey respondents who received cytisinicline reported quitting smoking completely.

Key Points: 
  • Results presented from the Phase 3 participant surveys, showed that 69% of survey respondents who received cytisinicline reported quitting smoking completely.
  • For those on treatment that did not achieve full smoking abstinence, 22% reported a reduction of their smoking by over half.
  • Total operating expenses for the fourth quarter and year ended December 31, 2023 were $4.4 million and $27.3 million, respectively.
  • Total net loss for the fourth quarter and year ended December 31, 2023 was $5.5 million and $29.8 million, respectively.

Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024

Retrieved on: 
Thursday, March 28, 2024
Online, Cancer, Research, Lung cancer, IRS, Head, CSC, Tumor microenvironment, Biomarker, Abstract, AACR, Publication, Neoplasm, IGF1R, Drug resistance, Recurrence, STAT3, Escape Room, Neck, Pharmaceutical industry

REHOVOT, Israel, March 28, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it will present data for its oncology candidate NT219, a first-in-class small molecule, dual-inhibitor of IRS 1/2 and STAT3, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting which takes place April 5-11, 2024, in San Diego, California.

Key Points: 
  • “The growing body of clinical, biomarker, and preclinical data for NT219 demonstrate its potential not only in the lead indication of recurrent/metastatic squamous cell carcinoma of the head and neck, but also in other solid-tumor cancers.
  • These publications at AACR 2024 are a result of the progress made last year both in clinical and preclinical work bringing out NT219’s attributes,” stated Gil Efron, Chief Executive Officer of Purple Biotech.
  • “We look forward to leveraging these data as we move forward with the clinical evaluation of NT219.”
    Dr Hadas Reuveni, VP Research and Development at Purple Biotech, added, “At AACR 2024 we will present new data related to NT219.
  • The presented posters will be available on the Publications section of Purple Biotech’s website, following their presentations at the conference.

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Retrieved on: 
Thursday, March 28, 2024
BCG, American Urological Association, Disease, Carcinoma, Patient, Single, Mayo Clinic, Bladder cancer, University, Abstract, High Risk, Treatment, University of Texas System, AUA, Clothing

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that three abstracts highlighting cretostimogene will be presented at the American Urological Association (AUA) Annual Meeting, taking place at Henry B. González Convention Center in San Antonio, TX from May 3-6, 2024.

Key Points: 
  • IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that three abstracts highlighting cretostimogene will be presented at the American Urological Association (AUA) Annual Meeting, taking place at Henry B. González Convention Center in San Antonio, TX from May 3-6, 2024.
  • CG Oncology is exhibiting at the AUA meeting at booth #100.
  • “We are excited to share encouraging 12-month Phase 3 monotherapy results from the BOND-003 study at AUA 2024,” said Ambaw Bellete, President and Chief Operating Officer, CG Oncology.
  • “Our presence reinforces our commitment to improving outcomes for patients diagnosed with bladder cancer across the disease spectrum.”
    Details of the oral presentations are as follows:
    Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
    Presenter: Mark D. Tyson, M.D., Urologic Oncologist at Mayo Clinic, Scottsdale, AZ
    Presenter: Robert Svatek, M.D., Urologic Oncologist at University of Texas Health Science Center, San Antonio, TX
    BOND-003- Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
    Presenter: Mark D. Tyson, M.D., Urologic Oncologist at Mayo Clinic, Scottsdale, AZ

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, March 28, 2024
WEE1, Research, ACRV, Ovarian cancer, Carcinoma, Drug discovery, Patient, Neoplasm, Cell cycle, AP3, IC50, Proteomics, Abstract, AACR, PKMYT1, Clinical trial, Therapy, Toxicology, Mass spectrometry, GLP, Medicine, LDG, Pharmaceutical industry

“On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year for Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.

Key Points: 
  • “On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year for Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
  • We remain on track to present more mature clinical data during the first half of 2024.
  • Additionally, our novel WEE1/PKMYT1 inhibitor ACR-2316 continues to demonstrate robust and superior single-agent preclinical activity and tolerability as demonstrated in head-to-head benchmark studies.
  • As of December 31, 2023, the company had cash, cash equivalents and marketable securities of $127.5 million, which is expected to fund operations into the fourth quarter of 2025.

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

Retrieved on: 
Wednesday, March 27, 2024
Conference, ATS, Physicalism, SAN, University, American Thoracic Society, Abstract, Poster, Therapy

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company will present four scientific posters at the upcoming 2024 American Thoracic Society (ATS) International Conference, taking place in San Diego, California from May 17-22, 2024.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company will present four scientific posters at the upcoming 2024 American Thoracic Society (ATS) International Conference, taking place in San Diego, California from May 17-22, 2024.
  • The following abstracts are posted on ATS 2024’s online itinerary planner.
  • Presenter: Jonathan G. Goldin, M.D., Ph.D., Professor of Radiology, Medicine and Biomedical Physics at the David Geffen School of Medicine at the University of California, Los Angeles
    Pliant was also selected for a featured oral presentation as part of the ATS 2024 Mini Symposiums program.
  • Posters will be available to view during the ATS Conference, Sunday, May 19 - Wednesday, May 22.

Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University

Retrieved on: 
Tuesday, March 26, 2024
Tel Aviv University, Interdisciplinarity, Mental health, Research, FRA, Health Canada, Abstract, GMP, Quality, Ground substance, API, MDMA, Psychedelic drug, Pharmaceutical industry

In this collaboration, Optimi will supply IPR-TLV with MDMA, which was made from in-house produced active pharmaceutical ingredient (API), to support the institute's research investigating the effects of MDMA on animal models of alcohol addiction.

Key Points: 
  • In this collaboration, Optimi will supply IPR-TLV with MDMA, which was made from in-house produced active pharmaceutical ingredient (API), to support the institute's research investigating the effects of MDMA on animal models of alcohol addiction.
  • Optimi has received the import permit from IPR-TLV and is in the process of obtaining its export permit from Health Canada.
  • Expected to commence in the summer of 2024 and conclude in late 2025, this study aligns with Optimi's commitment to supplying MDMA to international researchers advancing mental health and addictions research.
  • Commenting on the collaboration, Optimi CEO Bill Ciprick expressed his enthusiasm, stating, "Our agreement with IPR-TLV signifies an exciting entry into the Israeli psychedelics research market for Optimi.

Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology

Retrieved on: 
Tuesday, April 9, 2024
Health, Other Science, General Health, Clinical Trials, Research, Science, Pharmaceutical, Hypersensitivity, Anaphylaxis, Angioedema, Brain, Eptinezumab, Virtual Private LAN Service, Headache, Patient, American Academy, Interview, MD, Neurology, Migraine, Lundbeck, Quality of life, AAN, Abstract, Pharmaceutical industry

These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.

Key Points: 
  • These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.
  • “Our real-world data helps us better understand how individuals are uniquely impacted by migraine beyond monthly headache days.
  • We’re excited to continually partner with the migraine community to raise the bar on preventive treatment expectations.”
    VYEPTI is indicated for the preventive treatment of migraine in adults.
  • The safety and efficacy of VYEPTI has not been evaluated for use in any psychiatric conditions.

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

Retrieved on: 
Tuesday, April 9, 2024
Health, Surgery, Genetics, Managed Care, General Health, Cardiology, Biotechnology, Patient, International Society, Caregiver, White, Transplant, Columbia University, University, University of Colorado, Lung transplantation, Heart transplantation, Abstract, Lung, Heart, NYU Langone Health, Stanford University, University Health Network, MAS, Loyola University, Medical device

CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.

Key Points: 
  • CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.
  • This includes AlloSure Heart, AlloMap Heart, HeartCare, AlloSure Lung, and AiCAV (in development); featured in over 25 oral presentations, posters, and two symposia.
  • These presentations will highlight real-world applications driving advancements in heart and lung transplantation.
  • “We are proud to have a leading presence once again at this pivotal heart and lung transplant meeting.